Ascendis appoints Mark Sardi as new CEO
The former Truworths CFO will take up the position on October 14 as the group disposes of assets and pursues a turnaround strategy
Former Truworths CFO Mark Sardi has been given the top job at Ascendis Health, which is trying to turn its operations around.
Sardi, a qualified chartered accountant, has extensive corporate finance and investment banking experience, and is equipped to lead the group as it prioritises the revitalisation of its underperforming businesses and seeks to improve cash management, Ascendis chair Andrew Marshall said in a statement on Monday.
Sardi was the joint head of investment banking at Nedbank Capital for five years, and had also been deputy CEO of generic pharmaceutical business Cipla SA.
Ascendis said on May 24 that it had parted ways with Thomsen, who had only been in the job for 14-months. The company's share had fallen 10.2% on the news, although it subsequently recovered.
Ascendis's share price had been under pressure due to debt concerns and forced selling by major shareholder Coast2Coast, which was forced to sell the shares to meet loan obligations to lenders.
On May 3, Ascendis said it had appointed Marshall and Phil Roux, the former CEO of Pioneer Foods, to its board.
The board changes came after a demand in late April by two significant shareholders — Mergence Investment Managers and Acanthin Capital — to convene a general meeting to nominate new nonexecutive directors to the board.
Ascendis’s share price was up 1.13% to R4.49 in afternoon trade.
The market appeared to be unperturbed by the announcement, and Sardi's experience in pharmaceutical sector, including generic medication, counted in his favour, Small Talk Daily's Anthony Clark said.
“He does have corporate finance expertise, and worked with some very large companies, even though his tenure may not be as long as one would desire for a company,” Clark said. “All in all this is a very interesting move,” he said.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.